Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies

Fleur A. de Groot, Tim J.A. Dekker, Jeanette K. Doorduijn, Stefan Böhringer, Mirian Brink, Ruben A.L. de Groen, Lorraine M. de Haan, F. J.Sherida H. Woei-A-Jin, Troy Noordenbos, Aniko Sijs-Szabo, Mirjam A. Oudshoorn, King H. Lam, Arjan Diepstra, Liane C.J. te Boome, Valeska Terpstra, Lara H. Bohmer, Alina Nicolae, Eduardus F.M. Posthuma, Lianne Koens, Marc F. DurianJeroen Stavast, Marjolein W.M. van der Poel, Myrurgia Abdul Hamid, Wendy B.C. Stevens, Sjo L.M. van Rooij, Rimke S. Oostvogels, Angelika Mühlebner, Karen J. Neelis, Michiel van den Brand, Thomas Tousseyn, Daan Dierickx, Okke de Weerdt, Aart Beeker, Patty M. Jansen, Marie José Kersten, Josée M. Zijlstra, Martine E.D. Chamuleau, Hendrik Veelken, Jacoline C.E. Bromberg, Marcel Nijland, Joost S.P. Vermaat*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Given the rarity of primary central nervous system lymphoma (PCNSL), evaluations of different high-dose methotrexate-(HD-MTX)-based treatment regimens is sparse. This retrospective, multicenter study evaluates clinical characteristics and outcomes (progression-free, overall and disease-specific survival) after five HD-MTX-based polychemotherapeutic regimens and two consolidation therapies. 346 patients with histologically confirmed PCNSL, treated with ≥ 1 cycle HD-MTX-based strategies (≥3g/m 2/cycle) were included. The regimens included MATRIX (HD-MTX, HD-AraC, thiotepa, and rituximab), (R)MBVP±HD-AraC (HD-MTX, teniposide/etoposide, carmustine, prednisolone, ± HD-AraC, ± rituximab), (R)MP (HD-MTX, procarbazine, ± rituximab), and a combination of HD-MTX and HD-AraC. The overall response rate after induction was 69 %, 28 % complete remission and progressive disease was observed in 100 (29 %) patients. 126 (36 %) patients received consolidation, including high-dose-BCNU-thiotepa with autologous stem cell transplantation (HD-BCNU-TT/ASCT, n = 59 (17 %)) or whole brain radiotherapy (WBRT, n = 67 (19 %)). Clinical characteristics associated with adverse mortality risk by multivariable prognostication contained age > 60 years (HR 1.61, p = 0.011), elevated LDH (HR 1.75, p = 0.004) and WHO status ≥ 2 (HR 1.56, p = 0.010). Independently, induction regimens containing HD-AraC demonstrated survival benefit compared to induction regimens without HD-AraC (HR 0.59, p = 0.002). Without preference for HD-BCNU-TT/ASCT or WBRT, a favorable effect of consolidation (HR 0.44 and HR 0.42, p < 0.001) was confirmed, also with consolidation as time-dependent variable. Competing risk analysis showed similar low incidence of lymphoma-unrelated deaths in consolidated and unconsolidated patients. This study confirms that age, elevated LDH and WHO status increase the mortality risk. HD-AraC containing treatment regimens and consolidation with HD-BCU-TT/ASCT or WBRT were associated with superior survival, including a favorable low incidence of lymphoma-unrelated deaths.

Original languageEnglish
Article number115068
Number of pages9
JournalEuropean Journal of Cancer
Volume213
DOIs
Publication statusPublished - 1 Dec 2024

Keywords

  • Clinical characteristics
  • Consolidation
  • High-dose methotrexate
  • Induction
  • PCNSL
  • Polychemotherapy
  • Survival outcomes

Fingerprint

Dive into the research topics of 'Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies'. Together they form a unique fingerprint.

Cite this